Sporadic Breast Cancer (SBC)
Among the various subtypes of breast cancer, sporadic breast cancer represents a significant portion of cases. Our company is dedicated to advancing the field of sporadic breast cancer therapeutics through our therapy diagnostics, therapy development, and preclinical research services.
Overview of Sporadic Breast Cancer (SBC)
Sporadic breast cancer (SBC) refers to breast cancer cases that do not have a known hereditary or familial component. Unlike hereditary breast cancer, which is caused by specific gene mutations like BRCA1 and BRCA2, sporadic breast cancer arises due to a combination of genetic and environmental factors. It is estimated that approximately 85-90% of breast cancer cases fall into the sporadic category.
Pathogenesis of Sporadic Breast Cancer (SBC)
While the exact cause of sporadic breast cancer remains elusive, several risk factors have been identified. These include advancing age, early menarche, late menopause, nulliparity, hormone replacement therapy, exposure to ionizing radiation, and lifestyle factors such as alcohol consumption and obesity.
Genetic alterations, such as somatic mutations and epigenetic modifications, also contribute to the development of sporadic breast cancer. Comprehensive genomic studies have revealed the involvement of various genes and pathways in sporadic breast cancer, including those regulating cell cycle control, DNA repair mechanisms, and signaling pathways associated with tumor growth and metastasis.
Fig. 1 KIT expression in the breast cancer. (Rahimi, Maryam, et al., 2020)Targeted Therapies of Sporadic Breast Cancer (SBC)
PI3K/AKT/mTOR Targeted Therapy
Dysregulation of the PI3K/AKT/mTOR pathway is commonly observed in sporadic breast cancer. Inhibitors targeting this pathway, such as everolimus, have shown promise in trials as a targeted therapy for sporadic breast cancer cases with PI3K/AKT/mTOR pathway alterations.
CDK4/6 Targeted Therapy
Aberrant activation of the CDK4/6 pathway is frequently observed in sporadic breast cancer, promoting cell cycle progression and tumor growth. CDK4/6 inhibitors, such as ribociclib, palbociclib, and abemaciclib, have emerged as effective therapies, particularly in ER-positive, HER2-negative sporadic breast cancer.
HER2 Targeted Therapy
Amplification of the HER2 (Human Epidermal Growth Factor Receptor 2) gene occurs in a subset of sporadic breast cancers, leading to overexpression of the HER2 protein. Therapies targeting HER2, such as trastuzumab and pertuzumab, have revolutionized the treatment of HER2-positive sporadic breast cancer.
ER Targeted Therapy
Estrogen receptor (ER)-positive breast cancers account for a significant proportion of sporadic breast cancer cases. Targeting the ER pathway with endocrine therapies, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), has been a cornerstone in the management of ER-positive sporadic breast cancer.
Our Services
At our company, we are committed to providing cutting-edge diagnostics and therapy development services. Our state-of-the-art laboratory facilities and team of experienced scientists enable us to provide comprehensive solutions to our clients.
Therapy Development Platforms
Animal Models of Sporadic Breast Cancer
Preclinical research plays a vital role in assessing the effectiveness and safety of potential therapies. Our Company offers comprehensive animal model development and preclinical research services to facilitate the development of novel therapies for sporadic breast cancer.
| Induced Disease Model Development | |
| Our company excels in developing induced models utilizing various methods to artificially induce breast tumors in animals. These models enable researchers to investigate specific genetic, environmental, and hormonal factors contributing to breast cancer development. | |
| Optional Models | Chemical Induction Model, Physical Induction Model, Biological Induction Model |
| Xenograft Model Development | |
| Transplantation models, particularly xenograft models, offer a unique opportunity to study human breast cancer in vivo. Our company specializes in developing transplantation models using immunodeficient mice, such as nude mice and SCID mice, which provide an ideal environment for the growth of human breast cancer cells. | |
| Optional Species | Mouse, Rat, Dog, Cat, Pig, Tree Shrews, Caenorhabditis Elegans, Drosophila, Zebrafish, Others |
In addition, we also provide other customized animal models to meet diverse needs. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Rahimi, Maryam, et al. "The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer." Reports of Biochemistry & Molecular Biology 9.1 (2020): 40.
- Mathias, Carolina, et al. "Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability." Scientific Reports 10.1 (2020): 16614.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.